Gyre Therapeutics Book Value Per Share Growth & History (GYRE)
Gyre Therapeutics's book value per share was $0.68 for fiscal 2025.
View full Gyre Therapeutics company overviewGyre Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.68 | -$0.05 | −6.71% |
| 2024 | 2024-12-31 | $0.73 | $0.94 | — |
| 2023 | 2023-12-31 | -$0.21 | -$0.88 | — |
| 2022 | 2022-12-31 | $0.67 | -$0.64 | −48.88% |
| 2021 | 2021-12-31 | $1.31 | -$2.13 | −62.00% |
| 2020 | 2020-12-31 | $3.44 | -$2.23 | −39.35% |
| 2019 | 2019-12-31 | $5.68 | -$4.36 | −43.44% |
| 2018 | 2018-12-31 | $10.03 | $4.97 | +98.27% |
| 2017 | 2017-12-31 | $5.06 | -$14.98 | −74.75% |
| 2016 | 2016-12-31 | $20.04 | -$21.20 | −51.39% |
| 2015 | 2015-12-31 | $41.24 | $4,463.15 | — |
| 2014 | 2014-12-31 | -$4,421.91 | -$251.87 | — |
| 2013 | 2013-12-31 | -$4,170.03 | -$379.80 | — |
| 2012 | 2012-12-31 | -$3,790.24 | -$10,916.63 | — |
| 2011 | 2011-12-31 | $7,126.39 | $2,783.88 | +64.11% |
| 2010 | 2010-12-31 | $4,342.51 | $669.11 | +18.22% |
| 2009 | 2009-12-31 | $3,673.40 | — | — |
Gyre Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.02 | $0.00 | +0.46% |
| Q1 2026 | 2026-03-31 | $1.11 | $0.33 | +42.69% |
| Q4 2025 | 2025-12-31 | $0.68 | -$0.05 | −6.71% |
| Q3 2025 | 2025-09-30 | $1.12 | $0.38 | +52.23% |
| Q2 2025 | 2025-06-30 | $1.01 | $0.31 | +43.61% |
| Q1 2025 | 2025-03-31 | $0.78 | $0.11 | +17.24% |
| Q4 2024 | 2024-12-31 | $0.73 | $0.94 | — |
| Q3 2024 | 2024-09-30 | $0.74 | $1.52 | — |
| Q2 2024 | 2024-06-30 | $0.71 | $1.45 | — |
| Q1 2024 | 2024-03-31 | $0.66 | $1.35 | — |
| Q4 2023 | 2023-12-31 | -$0.21 | -$0.88 | — |
| Q3 2023 | 2023-09-30 | -$0.78 | -$1.72 | — |
| Q2 2023 | 2023-06-30 | -$0.75 | -$3.26 | — |
| Q1 2023 | 2023-03-31 | -$0.69 | -$1.55 | — |
| Q4 2022 | 2022-12-31 | $0.67 | -$0.64 | −48.88% |
| Q3 2022 | 2022-09-30 | $0.93 | -$1.82 | −66.06% |
| Q2 2022 | 2022-06-30 | $2.51 | -$0.20 | −7.54% |
| Q1 2022 | 2022-03-31 | $0.86 | -$2.46 | −74.10% |
| Q4 2021 | 2021-12-31 | $1.31 | -$2.13 | −62.00% |
| Q3 2021 | 2021-09-30 | $2.75 | -$1.51 | −35.47% |
| Q2 2021 | 2021-06-30 | $2.72 | -$2.22 | −45.02% |
| Q1 2021 | 2021-03-31 | $3.32 | -$2.28 | −40.66% |
| Q4 2020 | 2020-12-31 | $3.44 | -$2.23 | −39.35% |
| Q3 2020 | 2020-09-30 | $4.26 | -$2.50 | −36.95% |
| Q2 2020 | 2020-06-30 | $4.94 | -$2.81 | −36.27% |
| Q1 2020 | 2020-03-31 | $5.60 | -$3.24 | −36.65% |
| Q4 2019 | 2019-12-31 | $5.68 | -$4.36 | −43.44% |
| Q3 2019 | 2019-09-30 | $6.76 | -$4.13 | −37.91% |
| Q2 2019 | 2019-06-30 | $7.75 | -$3.71 | −32.39% |
| Q1 2019 | 2019-03-31 | $8.84 | -$3.13 | −26.17% |
| Q4 2018 | 2018-12-31 | $10.03 | $4.97 | +98.27% |
| Q3 2018 | 2018-09-30 | $10.88 | $5.11 | +88.51% |
| Q2 2018 | 2018-06-30 | $11.47 | $4.43 | +62.90% |
| Q1 2018 | 2018-03-31 | $11.97 | -$1.87 | −13.49% |
| Q4 2017 | 2017-12-31 | $5.06 | -$14.98 | −74.75% |
| Q3 2017 | 2017-09-30 | $5.77 | -$18.86 | −76.57% |
| Q2 2017 | 2017-06-30 | $7.04 | -$23.58 | −77.01% |
| Q1 2017 | 2017-03-31 | $13.84 | -$22.90 | −62.33% |
| Q4 2016 | 2016-12-31 | $20.04 | -$21.20 | −51.39% |
| Q3 2016 | 2016-09-30 | $24.64 | -$22.95 | −48.23% |
| Q2 2016 | 2016-06-30 | $30.62 | -$3,975.16 | −99.24% |
| Q1 2016 | 2016-03-31 | $36.73 | -$4,123.39 | −99.12% |
| Q4 2015 | 2015-12-31 | $41.24 | $4,463.15 | — |
| Q3 2015 | 2015-09-30 | $47.59 | -$4,513.04 | −98.96% |
| Q2 2015 | 2015-06-30 | $4,005.78 | -$720.82 | −15.25% |
| Q1 2015 | 2015-03-31 | $4,160.12 | -$853.93 | −17.03% |
| Q4 2014 | 2014-12-31 | -$4,421.91 | -$251.87 | — |
| Q3 2014 | 2014-09-30 | $4,560.63 | -$1,390.05 | −23.36% |
| Q2 2014 | 2014-06-30 | $4,726.60 | -$1,692.43 | −26.37% |
| Q1 2014 | 2014-03-31 | $5,014.06 | -$1,866.64 | −27.13% |
| Q4 2013 | 2013-12-31 | -$4,170.03 | -$379.80 | — |
| Q3 2013 | 2013-09-30 | $5,950.68 | -$1,789.78 | −23.12% |
| Q2 2013 | 2013-06-30 | $6,419.03 | -$1,599.11 | −19.94% |
| Q1 2013 | 2013-03-31 | $6,880.69 | -$423.03 | −5.79% |
| Q4 2012 | 2012-12-31 | -$3,790.24 | -$10,916.63 | — |
| Q3 2012 | 2012-09-30 | $7,740.46 | $297.16 | +3.99% |
| Q2 2012 | 2012-06-30 | $8,018.14 | $283.52 | +3.67% |
| Q1 2012 | 2012-03-31 | $7,303.72 | — | — |
| Q4 2011 | 2011-12-31 | $7,126.39 | $2,783.88 | +64.11% |
| Q3 2011 | 2011-09-30 | $7,443.30 | — | — |
| Q2 2011 | 2011-06-30 | $7,734.62 | — | — |
| Q4 2010 | 2010-12-31 | $4,342.51 | — | — |
Gyre Therapeutics book value per share trends
Over the last five fiscal years, Gyre Therapeutics's book value per share decreased from $3.44 to $0.68, a change of -$2.76. The latest reported quarter, Q2 2026, shows $1.02.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gyre Therapeutics source filings ↗